In the same meta-analysis SGLT-2 were superior to GLP-1 receptor agonists in terms of reducing hospitalization for HF and the composite renal outcome, while GLP-1 receptor agonists were the only drug that reduced non-fatal stroke (69). The gene discussed is GLP1R; the disease is Stroke.